Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m rituximab
- Development stage
- Unknown
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intradermal
01
Overview
technetium-99m rituximab is a radiolabeled monoclonal antibody used as a diagnostic imaging agent. It consists of the chimeric anti-CD20 monoclonal antibody rituximab labeled with the gamma-emitting radionuclide technetium-99m (99mTc), often via a chelator such as HYNIC (hydrazinonicotinamide) or through direct reduction methods. The agent specifically targets the CD20 antigen, which is highly expressed on B lymphocytes in lymph nodes and certain tumor cells. It is primarily developed and evaluated for sentinel lymph node (SLN) mapping and lymphoscintigraphy in patients with breast cancer, melanoma, and oral squamous cell carcinoma, offering high retention in the sentinel nodes and rapid clearance from the injection site.
- Other names
- 99mTc-HYNIC-rituximab99mTc-Rituximabtechnetium (99mTc) rituximabtechnetium-99m-labeled rituximabtechnetium99m-labeled rituximabtechnetium 99m-labeled rituximab
02
Targets
Beyond the preview
Go deeper on technetium-99m rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m rituximab.